Their team tackled the subject of gene augmentation, where a defective gene is replaced with a normal one; for example, EGFR gelatin nanoparticles were used to deliver p53 genes to PC cancer cells; the nanocomplex was proven to augment the apoptosis of the cancer cells; to the same effect, gelatin nanoparticles with gemcitabine were used to deliver p53 genes, which resulted in a 77.3% tumor growth inhibition. This evidence concerns the gene EGFR and cancer.